Category: 3. Business

New digital exhibition delivers a curated selection of artwork from seven of the world’s top galleries to living rooms worldwide

Samsung Art TV users gain access to fifth Art Basel digital art collection, exhibiting global reach of artists and galleries showcased

 

Samsung Electronics Co., Ltd., global display leader and provider of the Official Art TV of Art Basel, today announced the launch of the 2025 Art Basel Miami Beach Collection, a curated digital exhibition spotlighting 24 contemporary artists who will be showcased at Art Basel Miami Beach in December, available exclusively on Samsung Art Store^[1]

 

“With the 2025 Art Basel Miami Beach collection, we wanted to bring the distinct energy of the show directly into people’s homes,” said Daria Greene, Head of Content and Curation for Samsung Art Store. “Each artwork carries its own cultural perspective, expanding the ever-growing collection we offer on Samsung Art Store.”

 

The new 2025 Art Basel Miami Beach Collection features artwork by emerging and established artists from around the world, presented by seven of the world’s top galleries — Instituto de Visión, Kurimanzutto, Meredith Rosen Gallery, Nina Johnson, Vermelho, Sean Kelly and Charlie James Gallery. The hand-selected digital collection reflects the cultural richness and diverse voices that define contemporary art today.

 

Highlights include:

 

• Olinda Silvano, “Energía de la visión de Ayahuasca” (2022)
• The Pérez Bros., “Victoria Park” (2025)
• George Nelson Preston, “Apenas Cinco Semanas Da Kissama e as Colinas Do Brasil Nos Surpreenderam” (2019)
• Jennifer Rubell, “40 Hearts” (2018)
• Aycoobo, “Luna Ilena” (2024)

 

This is the fifth Art Basel digital art collection featured on Samsung Art Store. As part of Samsung’s longstanding partnership with the show, each collection aims to reflect the global reach of artists and galleries showcased at Art Basel, bringing that discovery directly into homes worldwide across the Samsung 2025 TV lineup.

 

“Art Basel’s partnership with Samsung continues to expand the ways in which our galleries and artists can reach new audiences,” said Vincenzo de Bellis, Chief Artistic Officer and Global Director of Art Basel Fair. “By bringing a curated selection from Art Basel Miami Beach into homes around the world, this initiative extends the fair’s artistic vision beyond the halls of the convention center and broadens the possibilities for discovery, engagement and visibility. We are delighted to see these works presented on Samsung Art Store, reflecting the depth of our exhibitors, the global resonance of their artists and the evolving formats through which contemporary art is experienced today.”

 

Samsung has led the global TV market for 19 consecutive years^[2], delivering the exceptional picture quality that fine art demands. Samsung Art Store features more than 4,000 works by over 800 artists, including the 2025 Art Basel Miami Beach Collection.

 

For more information, visit http://www.samsung.com/uk

 

[1]Art Store subscription and Samsung Account connection required to access full selection of artwork.

[2]Source: Omdia, Feb-2025 (Results are not an endorsement of Samsung)

• B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, respectively
• Deep and durable regressions observed with IDE034 monotherapy in multiple preclinical in-vivo models with B7H3 and PTK7 co-expression
• Enhanced durability with IDE034 and IDE161 PARG inhibitor combination in preclinical in vivo models; targeting to share additional preclinical data supporting mechanistic rationale at a medical conference in H1 2026

SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 1, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody-drug conjugate (ADC).  IDEAYA expects to begin enrolling the study in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck and ovarian/gynecological cancers.  Based on the Human Protein Atlas database, B7H3/PTK7 has been reported to be co-expressed in lung, colorectal, and head and neck cancers at approximately 30%, 46% and 27%, respectively.

“IND clearance for IDE034 is an important step in expanding our potential first-in-class TOP1 ADC clinical pipeline into bispecific, precision-guided approaches,” said Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer of IDEAYA Biosciences. “IDE034 has demonstrated robust antitumor activity and selective targeting of B7H3- and PTK7-expressing solid tumor models. The high prevalence of B7H3/PTK7 co-expression in solid tumors such as lung, colorectal, and head and neck cancers underscores its broad indication potential.”

“We are excited to advance our differentiated clinical strategy with now three potentially first-in-class clinical-stage programs focused on enhancing the efficacy of TOP1 ADCs through the PARG DDR combination mechanism.  We believe this approach addresses a key unmet need by improving the durability of response to TOP1 payload-based ADC therapies.  We are targeting to share additional preclinical data to support the PARG and TOP1 ADC combination rationale at a major medical conference in H1 2026,” said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.

Preclinical studies have demonstrated strong anti-tumor activity in B7H3/PTK7-positive tumor models, including deep and durable tumor regressions with IDE034 monotherapy, supporting advancement into clinical development. This co-expression pattern supports the potential for broad monotherapy activity, while the TOP1 payload provides a strong mechanistic rationale for combining IDE034 with IDEAYA’s PARG inhibitor, IDE161.  TOP1 inhibition induces replication stress and DNA damage, which can increase reliance on the PARG pathway; therefore, a IDE034 and IDE161 combination approach may enhance anti-tumor activity in patients with solid tumors that co-express B7H3 and PTK7, consistent with the results that were observed preclinically with this combination.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to: (i) the timing of the initiation of and enrollment of subjects for  the Phase 1 clinical trial to evaluate IDE034; (ii) the potential frequency of B7H3/PTK7 co-expressed in solid tumors types, including lung, colorectal, and head and neck cancers; (iii) the potential therapeutic benefit of IDE034 as monotherapy and in combination with IDE161, a PARG inhibitor; and (iv) the timing of a data presentation related to the  IDE034 and IDE161, PARG inhibitor, combination at a medical conference.  Preclinical study results are not necessarily predictive of future clinical trial results and/or approval.  Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA’s ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA’s Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact
Joshua Bleharski, Ph.D.
Chief Financial Officer 
[email protected]

SOURCE IDEAYA Biosciences, Inc.

Regulated Open Banking has gone live in New Zealand as part of a phased rollout, “opening the door” to faster loan approvals, easier bill management, and personalised budgeting insights, according to Commerce and Consumer Affairs Minister Scott Simpson.

Open Banking in the country is supported by a set of regulations established under the Customer and Product Data Act 2025.

Released in October, the regulations require the four major banks – ANZ, ASB, BNZ and Westpac – to have certain Open Banking systems ready by 1 December 2025, while Kiwibank will need to be ready by June 2026 for payments, and by December 2026 for other Open Banking services.

“From budgeting tools to faster mortgage comparisons and low-cost payment options, the opportunities and innovations presented by Open Banking are endless,” Simpson said.

“Open Banking makes it easier to switch banks by giving customers a safe, regulated way to share their financial information.

“It will make mortgage applications faster by allowing third-party services to securely gather the right financial documents in one place, especially helpful for people with accounts across different banks.”

The Minister also pointed to the benefits for small businesses in New Zealand.

“Small businesses will also benefit from more choice in financial management and invoicing tools, helping them get paid faster and access innovative, lower-cost payment solutions,” he said.

The Ministry of Business, Innovation and Employment (MBIE), which is providing regulatory oversight of the regime, is accepting applications from organisations that want to become accredited data requestors. In turn, they will receive an ‘accreditation mark’ from MBIE to show they are trusted and verified.

Simpson said: “The regulations, released in October, align with global best practice and build on successful models in Australia and the UK, where Open Banking has sped up home loan approvals and enabled new consumer-friendly apps.

“Importantly, the regulations ensure that security of consumer data is paramount. Data can only be shared under the customer’s explicit consent, and third-party requestors (such as fintechs) must be accredited by the Ministry of Business, Innovation and Employment.”

Further reading: Westpac NZ becomes first bank to hit key Open Banking milestone

Introduction

The Global Cancer Statistics 2022 report indicated that there were nearly 20 million new cancer cases, including 1.9 million new colorectal cancer (CRC) cases, accounting for nearly one-tenth of cancer cases, making it the third most common malignant tumor in the world and the second leading cause of cancer-related deaths.¹ With advances in minimally invasive techniques, locally advanced colorectal cancer (LARC) patients may benefit from neoadjuvant therapy. However, in the presence of metastases, chances of survival are significantly reduced.² Most LARC patients were treated with total mesolectal excision (TME) and neoadjuvant chemoradiotherapy (NACRT) significantly improved the distant metastasis of the cancer.³ The 5-year survival rate and cumulative incidence of 5-year local recurrence of 76% and 6%, respectively, with NACRT prior to TME reduced local recurrence, metastasis, and improved survival of patients with LARC.⁴ This treatment achieved a high pathological complete remission rate (pCR) (44.3%), a high CRT compliance rate (98.8%), and significantly fewer postoperative complications than the TME group.⁵ Therefore, NACRT, followed by resection of en bloc rectum and mesorectum, has become the standard of care for LARC.³

Different factors have a significant role in the stage reduction of LARC after NACRT-TME. Several studies have shown that from a radiation oncology point of view, radiomics column maps of MRI predict good response to NACRT,⁶ and that short-term radiation therapy and long-term chemotherapy not only increase the local response to NACRT but also reduce the risk of systemic recurrence.⁷ In terms of hematological indices, carcinoembryonic antigen (CEA), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-neutrophil index (PNI)⁸ and CRP albumin-lymphocyte index (CALLY) were all recently proposed as novel inflammation-nutrition composite index.⁹ CALLY has been shown to have a critical role in gastric, hepatic and pot-bellied cancers.^9–11 Regarding sarcopenia, which is characterized by loss of skeletal muscle mass (SMA), it is associated with progression-free survival (PFS) and overall survival (OS) in short-term CRC patients undergoing surgery.^12,13

The above factors indicate that inflammatory nutritional indices are key determinants influencing cancer progression and prognosis and possess predictive capacity for postoperative PFS and OS in CRC patients. Unfortunately, no existing models are currently available to assess the risk of NACRT and postoperative outcomes in LARC, thereby limiting the provision of valuable post-treatment guidance. In this study, we developed nomograms combining clinical factors and inflammatory nutritional indices to comprehensively evaluate disease prognosis outcomes. It can predict the probability of recurrence or death in specific individuals, and its most important advantage is that it can assess the risk of clinical events independently based on patient and disease characteristics.¹⁴ Nomograms can incorporate continuous variables and independent risk factors of the disease into prognosis, outperforming clinicians in assessing locally advanced tumors and is widely applicable in practice.¹⁵

Materials and Methods

Patients and Participants

This study retrospectively investigated patients with LARC who were treated with NACRT between January 2020 and May 2024 at Jiangnan University Hospital. The inclusion criteria were as follows: (1) patients with complete peripheral blood cell count data and serum CEA; (2) patients aged 18–79 years; (3) patients diagnosed with LARC after pathological histology, illnesses intestinal obstruction, distant metastases (lung/ovarian/peritoneal), or concurrent bone marrow transplantation during NACRT; patients who were unable to undergo surgery and opted for conservative treatment after NACRT; critically ill patients suffering from cardiac failure, renal failure, or other serious illnesses; and patients with incomplete follow-up data were excluded from the analysis (Figure 1). All patients were staged preoperatively with contrast-enhanced computed tomography of the abdomen and pelvis using MRI of the pelvis and contrast-enhanced computed tomography CT. Pathologic histology of all patients was staged, according to the 8th AJCC TNM. Clinical staging before the start of NACRT (cTNM) was compared with the pathology of the resected specimens after treatment (ypTNM), down to ypTNM stage 0-I as the criterion for grouping.¹⁶ Owing to the specific nature of the disease, the sample size only met the minimum power requirement; however, multicenter studies on rare subgroups will be required in the future.

Figure 1 Study flow chart. Abbreviations: LARC, locally advanced colorectal cancer; NACRT, neoadjuvant chemoradiotherapy.

Treatment Strategies

All patients received a NACRT regimen consisting of a total radiation dose of 45 or 50.4 Gy and continuous infusion or oral (capecitabine) 5-fluorouracil chemotherapy-based chemotherapy. Radiotherapy was delivered in 25 fractions over 5 weeks.¹⁷ Surgery was performed for at least 6 weeks after the last radiotherapy session. All cases were treated by open or laparoscopic surgery. Surgical approaches included Dixon’s procedure, colostomy, Hartmann’s procedure, and Miles’ procedure. Based on pre-NACRT imaging, if lateral pelvic lymph node (LLN) metastasis was suspected, lateral pelvic lymph node dissection was performed concurrently. Adjuvant chemotherapy was considered for all patients regardless of pathological results. The regimen used for adjuvant chemotherapy was as follows: the Roswell Park regimen of intravenous 5-FU plus LV, oral UFT plus l-LV, or oral capecitabine plus oxaliplatin, capecitabine plus oxaliplatin.¹⁸

Date Collection

The following data were collected: (1) Baseline clinical variables: gender, age, Diabetes, Hypertension, body mass index (BMI), Charlson comorbidity index (CCI), nutritional risk screening 2002 (NRS2002) score and L3 skeletal muscle cross-sectional area (L3SM). (2) pre-NACRT, serologic parameters within 24 hours of admission: platelet count, lymphocyte count, neutrophil count, monocyte count, albumin count, C-reactive protein (CRP), CEA, carbohydrate antigen 19–9 (CA199) et al (3) Pathological information: TNM stage before and after NACRT, vascular invasion and nerve invasion et al (4) Follow-up data: overall survival (OS) and progression-free survival (PFS) (months). We calculated L3SMI, NLR, PLR, LMR, PNI and CALLY according to the following formula.

Slice-Omatic, version 5.0 (TomoVision, Magog, Canada) was used to analyse L3SM on CT images. Muscle tissue unit thresholder ranged from −29 HU to 150 HU. L3SMI (cm²/m²) = total area of all skeletal muscle at the L3 level (cm²)/height² (m²).^19,20 CALLY index = (albumin level in g/L) × (lymphocyte count in/μL)/(CRP level in mg/L) × 10.²¹ The formulas for the remaining inflammatory nutritional indices were presented in Supplementary Table S1.

Complication Assessment

Postoperative complications following LARC radical surgery are defined as medical or surgical complications occurring within 30 days postoperatively. The Claven-Dindo system is used for grading (Supplementary Table S2), with grade ≥ IIIa classified as severe postoperative complications.²² CCI includes all postoperative adverse events, which are weighted according to severity and comprehensively calculated (www.assessurgery.com) to derive the corresponding score (0–100 points, with 0 points indicating no complications and 100 points indicating death).^23,24

Endpoints and Follow-Up

All patients were followed by telephone and in the clinic. The endpoints event defined as any form of tumour recurrence, metastasis or death, with a follow-up deadline of May 2025. The primary endpoint of this study was OS, defined as the time interval from the date of randomization to death from any cause. The secondary endpoint was PFS, defined as the time from the start of treatment to the first imaging-confirmed disease progression or death from any cause.

Establishment and Validation of Prognostic Models

LASSO regression was used for preliminary analysis, and the selected variables were further screened using univariate Cox analysis to identify potential risk factors affecting survival. After identifying the potential risk factors, we performed backward multivariate analysis to select the optimal model. Based on the results of the multivariate Cox, statistically significant variables (P < 0.05) were included in the nomogram to predict 2-year and 3-year survival rates after NACRT and surgery. The predictive performance of the nomogram model was assessed using time-dependent receiver operating characteristics (ROC), bootstrap method and calibration curves. Time-dependent ROC were used to evaluate discriminatory ability. Bootstrap method was used to repeat 500 times for internal validation of the nomogram model. Calibration curves were used to compare the probabilities predicted by the nomogram with actual outcomes. Kaplan–Meier curves (KM) was used to validate the risk stratification ability of the nomogram model. Finally, the net benefit of the model was assessed using decision curve analysis (DCA).

Statistical Analysis

Statistical analysis was performed using SPSS 27.0 software. For continuous variables, normality was tested using the Kolmogorov–Smirnov test. Compliance was expressed as mean ± standard deviation (SD) for continuous variables and as median M [P25, P75] for non-continuous variables. For categorical variables, categorical information was presented as numbers and percentages (n,%). Comparisons between groups were performed using independent samples t-tests, non-parametric rank-sum tests, and chi-square (χ²) tests. ROC curves were plotted, and the Youden index was calculated to identify the optimal cutoff value for the inflammatory nutritional index in predicting survival. LASSO regression was used for preliminary screening of potential risk factors, followed by Cox proportional hazards models for univariate and multivariate analysis. Forest plots were created using the Dream Cloud statistical platform (https://mengte.pro/forest_plot), and the model was visualized using a nomogram. The calibration curve, bootstrap method and DCA were used to evaluate the model. All analyses were conducted using R (version 4.5.0; http://www.r-project.org/), with a two-sided P < 0.05 indicating statistical significance.

Results

Baseline Characteristics and ROC Curves That Affect the Survival

The baseline characteristics of LARC patients included in this retrospective study are presented in Table 1. The median OS and PFS for all patients were 27 months and 26 months, respectively. The 2-year and 3-year OS rates were 93.9% and 79.3%, respectively. The 2-year and 3-year PFS rates were 76.7% and 52.8%, respectively. Among the 131 patients (95 male, 36 female), the median age of LARC patients was 62 years [IQR: 55, 70]. According to the 8th AJCC TNM classification, postoperative histopathology showed that ypTNM stage 0-I was defined as a good response, and ypTNM stage II–IV was defined as a poor response. Moreover, according to postoperative pathology findings, the results showed that six inflammatory nutritional indices, the quantitative indicator CCI for complications occurring within 30 days postoperatively in 101 LARC patients (77.1%); histological differentiation, with moderate differentiation (71.7%); and no vascular invasion (77.9%) were significantly associated with tumor downstaging. All patient characteristics are listed in Table 1.

Table 1 Baseline Data and Clinicopathologic Features

According to ROC analyses, the optimal cutoffs for predicting survival using L3SMI, PLR, NLR, LMR, CALLY, and PNI were 43.44, 152.09, 2.83, 3.09, 1.47, and 45.85, respectively. The optimal inflammatory nutritional index for predicting survival was CALLY (AUC = 0.736, 95% CI: 0.609–0.863; P < 0.001). All inflammatory nutritional indices are listed in Figure 2 and Table 2.

Table 2 AUC Values from the ROC Analysis of Inflammatory Nutritional Indices for Predicting Survival

Figure 2 Receiver operating characteristic curves of inflammatory nutritional indices for predicting survival. The highest area under curve (AUC) value for survival is CALLY (0.736). Abbreviations: L3SMI, L3 Skeletal Muscle Index; PNI, prognostic nutrition index; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; CALLY, C-reactive protein-albumin-lymphocyte index.

LASSO Regression Screening for Prognostic Factors of OS and PFS in LARC

By comparing the clinical characteristics of LARC patients undergoing NACRT and whether the tumor stage was downgraded post-surgery (Table 1), multiple potential prognostic factors were identified, including gender, age, diabetes, hypertension, BMI, NRS2002 score, CCI, and 19 other indicators. These factors were included in LASSO regression analysis, and the optimal assessment indicator for OS was achieved when the harmonic parameter log(λ) was 0.033. Ultimately, 17 variables were selected: gender, age, BMI, NRS2002, CCI, CEA, N stage, L3SMI, PLR, NLR, LMR, CALLY, PNI, histological differentiation, vascular and nerve invasion, and Her-2 (Figure 3A and B). These clinical characteristics were found to be associated with OS in LARC patients. Similarly, the optimal assessment indicator for PFS was achieved when the harmonic parameter log(λ) was 0.084, and ultimately 7 variables were selected that were associated with PFS: CEA, CA724, PLR, CALLY, histological differentiation, vascular invasion, and nerve invasion (Figure 3C and D).

Figure 3 A LASSO binary Cox regression model based on the minimum Lambda value was used to screen predictive indices for overall survival (OS) and progression-free survival (PFS) in LARC patients. (A) LASSO coefficient parameter for the 28 variables predicting OS. Vertical lines are drawn at the values selected by 10-fold cross-validation in (B). As the λ value decreases, the model’s compression increases, enhancing its ability to select important variables. (B) 10-fold cross-validation results for predicting OS. The values between the two dashed lines represent the positive and negative standard deviation ranges of log(λ). The left dashed line indicates the value of the harmonic parameter log(λ) when the model error is minimized. When log(λ) = 0.033, 17 variables were selected. (C) LASSO coefficient parameters for the 28 variables predicting PFS. Vertical lines are drawn at the values selected in the 10-fold cross-validation in (D). As the λ value decreases, the model’s accuracy also decreases. (D) 10-fold cross-validation results for predicting PFS. When log(λ) = 0.084, 7 variables were selected.

Prognostic Prediction of the CALLY Index in LARC

We performed Cox regression analysis using the variables selected through Lasso regression analysis. The results of univariate and multivariate Cox regression analysis were presented in Figure 4. Multivariate analysis of OS showed (Figure 4A) that elevated levels of high CALLY (HR = 0.344, 95% CI: 0.133–0.893; P = 0.028) reduced the risk of OS by 65.6%. For the PFS multivariate analysis results (Figure 4B), high CALLY (HR = 0.492, 95% CI: 0.266–0.912; P = 0.024) reduced the risk of PFS by 50.8%. Additionally, we found that CEA is not only a risk factor for OS (HR = 1.004, 95% CI: 1.001–1.007; P = 0.014) but also PFS (HR = 1.005, 95% CI: 1.002–1.008; P < 0.001).

Figure 4 Multivariate Cox regression forest plot analyzing the survival prognosis of LARC patients based on the LASSO regression model. (A) Forest plot obtained from univariate and multivariate Cox regression analysis with OS as the outcome. (B) Forest plot obtained from univariate and multivariate Cox regression analysis with PFS as the outcome. Abbreviations: LARC, locally advanced colorectal cancer; CCI, Charlson comorbidity index; CA724, carbohydrate Antigen 72–4; L3SMI, L3 Skeletal Muscle Index; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNI, prognostic nutrition index; CALLY, C-reactive protein-albumin-lymphocyte index. Notes: *Indicate P < 0.05.

Development and Evaluation of Nomograms Based on CALLY

To develop a quantitative method for predicting the prognosis of LARC, we implement nomogram prediction models for OS and PFS based on the results of multivariate Cox analysis, including CALLY, CEA, and CCI (HR = 1.053, 95% CI: 1.000–1.108; P = 0.048) to predict the 2-year and 3-year OS of patients (Figure 5A), and CALLY, PLR (HR = 2.577, 95% CI: 1.321–5.027; P = 0.005), CEA, CA724 (per-unit increase HR = 1.006, 95% CI: 1.001–1.012; P = 0.023) and vascular invasion (HR = 2.263, 95% CI: 1.011–5.068; P = 0.047) to predict the 2-year and 3-year PFS of patients (Figure 6A). To utilize the nomogram, a vertical line is drawn from each variable’s value to the points axis, with total points calculated as the sum of all individual risk scores.

Figure 5 Comprehensive evaluation of the NACRT and postoperative OS prediction model for LARC patients: nomogram, calibration curve, and clinical decision curve (DCA). (A) Nomogram to predict 2-year and 3-year OS for LARC patients. (B) Time-ROC curves for 2-year and 3-year OS prediction based on the nomogram. (C) Calibration curves for 2-year and 3-year OS prediction based on the nomogram. The 45-degree diagonal line represents ideal prediction. (D and E) DCA of risk scores for OS prediction based on the nomogram. The net benefit, calculated by adding true positives and false positives, corresponds to the measurement value on the Y-axis; the X-axis represents the threshold probability. (D) 2-, (E) 3-year DCA for OS prediction based on the nomogram. Abbreviations: LARC, locally advanced colorectal cancer; NACRT, neoadjuvant chemoradiotherapy; CCI, Charlson comorbidity index; CALLY, C-reactive protein-albumin-lymphocyte index.

Figure 6 Comprehensive evaluation of the NACRT and postoperative PFS prediction model for LARC patients: nomogram, calibration curve, and clinical decision curve (DCA). (A) Nomogram to predict 2-year and 3-year PFS for LARC patients. (B) Time-ROC curves for 2-year and 3-year PFS prediction based on the nomogram. (C) Calibration curves for 2-year and 3-year PFS prediction based on the nomogram. The 45-degree diagonal line represents ideal prediction. (D and E) DCA of risk scores for PFS prediction based on the nomogram. The net benefit, calculated by adding true positives and false positives, corresponds to the measurement value on the Y-axis; the X-axis represents the threshold probability. (D) 2-, (E) 3-year DCA for PFS prediction based on the nomogram. Abbreviations: LARC, locally advanced colorectal cancer; NACRT, neoadjuvant chemoradiotherapy; CA724, carbohydrate Antigen 72–4; PLR, platelet to lymphocyte ratio; CALLY, C-reactive protein-albumin-lymphocyte index.

Model performance was evaluated using time-dependent ROC curves, calibration analyses, decision curve analysis (DCA) and bootstrap resampling method. The AUCs for 2- and 3-year OS predictions were 0.83 and 0.76, respectively (Figure 5B). However, the PFS model showed higher 3-year accuracy (AUC = 0.81), but lower 2-year accuracy (AUC = 0.71) compared to the OS model, respectively (Figure 6B). Calibration curves display the better consistency between predicted survival probabilities from the nomogram and the OS/PFS at 2- and 3-years (Figures 5C and 6C), indicating improved reliability in longer-term predictions. Furthermore, DCA shows that under the comparison of curve areas, the 3-year PFS model is much higher than that of the 2-year-3-year OS model (Figure 5D and E), which suggests that the value of the net benefit of the PFS model is much greater than that of the OS model, and even more strikingly, the 3-year PFS model exceeds the default strategy in terms of net benefit when the decision threshold exceeds 0.93 (Figure 6D and E). These results suggest that the PFS model improves the accuracy of long-term prognostic stratification and increases clinical value as the time horizon increases. At the same time, we performed internal validation of the models using the bootstrap resampling method 500 times and obtained the resampled ROC of the OS and PFS models: AUC = 0.866 (95% CI: 0.862–0.869) (Figure 7A); 0.861 (95% CI: 0.858–0.864) (Figure 7B). In summary, the nomogram model for PFS can better predict the value.

Figure 7 Bootstrap resampling 500 times for internal validation of the model. (A) Bootstrap resampling of the OS model 500 times, AUC = 0.866 (95% CI: 0.862–0.869); (B) Bootstrap resampling of the PFS model 500 times, AUC = 0.861 (95% CI: 0.858–0.864).

Survival Curves Based on the Nomograms

Patients were divided into low-risk and high-risk groups based on their survival status. Kaplan-Meier analysis showed that the two survival curves were significantly separated (Log rank test, P < 0.001). The OS and PFS rates indicated that the high-risk group had an 8.25 times higher risk of death (95% CI: 3.05–22.30) and a 6.98 times higher risk (95% CI: 3.75–12.99) compared to the low-risk group (Figure 8A and C). These results, along with the model, confirmed the clinical applicability of the nomogram. In addition, Kaplan-Meier curves for OS and PFS were plotted for CALLY (Figure 8B and D), showing that the risk of death in the low CALLY group was 3.99 times higher than that in the high CALLY group (95% CI: 1.437–10.80) and 2.89 times higher (95% CI: 1.335–6.259), respectively. In summary, compared to individual factors, the nomogram model can better predict OS and PFS.

Figure 8 Kaplan-Meier survival analysis based on nomogram risk groups and CALLY. (A) Nomogram risk stratification for predicting OS. The 5-year mortality risk in the high-risk group was 8.25 times higher than that in the low-risk group. (B) The effect of CALLY levels on OS. The mortality risk in the low CALLY group was 3.99 times higher than that in the high CALLY group. (C) Nomogram risk stratification for predicting PFS. The 5-year mortality risk in the high-risk group is 6.98 times higher than that in the low-risk group. (D) The impact of CALLY levels on PFS. The mortality risk in the low CALLY group is 2.89 times higher than that in the high CALLY group. Abbreviations: CALLY, C-reactive protein-albumin-lymphocyte index.

Discussion

The 5-year survival rate and 5-year cumulative local recurrence rate for LARC patients are 76% and 6%.⁴ The most effective treatment currently available involves NACRT followed by radical resection, with adjuvant chemotherapy administered subsequently. This approach improves preoperative tumor response rates and reduces postoperative local metastasis rates.²⁵ In short-term efficacy analyses, NACRT did improve the R0 resection rate and 3-year OS, but the distant metastasis rate remained high, and improvements in 5-year OS and disease-free survival (DFS) were not significant.²⁶ Therefore, as Okamura reported,²⁷ early identification of LARC with poor postoperative outcomes following NACRT, combined with adaptive treatment strategies, may improve the likelihood of tumor recurrence in the short term. While the Okamura model for esophageal cancer achieved an initial AUC of 0.679 with 1000 bootstrap validations of 0.670,²⁷ our nomogram demonstrates substantially improved discriminative ability in the LARC-specific context: initial 2-year AUC 0.830 further enhanced to 0.866 after 500 bootstraps (Figure 7A). This represents a relative improvement in predictive accuracy over current standards. We concluded that the model could enhance the treatment of NACRT patients by rapidly identifying high risk and then intervening with treatment regimens. In our study, we used OS and PFS as outcomes and analyzed 131 LARC patients using Lasso-Cox regression, screening out 3 and 5 variables respectively to establish two nomogram models predicting 2-year and 3-year outcomes. These indicators include tumor burden markers (CEA, CA724), inflammatory-nutritional markers (CALLY, PLR), and postoperative pathological and complication status (CCI, vascular invasion). The nomograms based on the inflammatory-nutritional index CALLY can rapidly stratify patients into risk groups prior to NACRT, thereby enabling individualized treatment.

Inflammation can promote carcinogenesis by inducing gene mutations, inhibiting apoptosis, stimulating angiogenesis and cell proliferation.²⁸ Mark Schmitt et al²⁹ demonstrated that even in the absence of exogenous carcinogens, inflammation itself can trigger tumor development by inducing DNA damage, and that part of the mechanism involves the release of innate immunity cells excessive reactive oxygen species leading to increased oxidative stress. CALLY, as an inflammatory nutritional index, has been reported to aid in the prognosis of various cancers.^9–11 It consists of CRP, serum albumin, and lymphocytes, playing a crucial role in inflammation, nutrition, and immunity in CRC.²¹ CRP and Alb are commonly used clinical markers for inflammation or nutrition. Previous studies had shown that elevated CRP levels indicated more severe inflammatory states and were closely associated with cancer prognosis.³⁰ Similarly, nutritional status should not be overlooked during cancer development. Inflammation can induce cancer, affecting metabolic processes and reducing the absorption and utilization of nutrition.³¹ Disease progression often leads to reduced food intake, and LARC may exhibit malnutrition or hypoproteinemia.³² This was highly consistent with our data: reduced CALLY values (reflecting elevated CRP and reduced albumin/lymphocytes) were independently associated with significant deterioration in 2- and 3-years OS and PFS. More importantly, our statistical analyses showed that CALLY demonstrated greater discriminatory power and comprehensive value in predicting the long-term survival prognosis of patients with LARC undergoing NACRT compared with CRP or Alb alone.

Surgery is a crucial step in the treatment of LARC-NACRT, and postoperative complications within 30 days can directly impact clinical outcomes and subsequent comprehensive treatment.³³ Slankamenac et al³⁴ first proposed the CCI scoring system in 2013, with a range of 0–100 points, offering a broader and more discriminative grading range for complications. David et al³⁵ reported that each one-point increase in CCI was associated with a 1.02-fold increase in risk, suggesting that CCI was an independent risk factor for postoperative outcomes in CRC. These findings were also validated in the present study, where CCI was closely associated with OS. Higher CCI scores (HR = 1.053, 95% CI: 1.000–1.108, P = 0.048) were associated with higher OS risk, indicating that patients with poorer baseline health status have a higher risk of postoperative mortality. Unlike CALLY, CCI is not a dynamic laboratory index but a clinical indicator reflecting the overall physiological reserve. Its value lies in its ability to indirectly reflect patients’ tolerance to treatment and postoperative recovery capacity, thereby predicting the prognosis of comprehensive treatment in the later stages.

Prognostic nomograms demonstrated superior versatility and efficiency in large-scale NACRT.³⁶ Our nomogram, integrating clinical serological markers, neoadjuvant strategies, postoperative pathology, genetic testing, and complication data effectively predicted OS and PFS in patients with LARC. Validation confirmed robust discriminatory performance that time-dependent ROC and bootstrap-validated AUC were all above 0.8. Additionally, calibration curves demonstrated close alignment with true outcomes, while DCA showed significant net benefit. It should be emphasized that the primary strength of models lies in their robust prediction of short-to-mid-term outcomes (AUC = 0.83 for 2-year OS), while extrapolation beyond 3 years remains limited by the current median follow-up of 27 months. Furthermore, based on the risk scores derived from the model, the high-risk group exhibited the worst prognosis. The risk stratification provided by this model directly guides precision treatment decisions. Low-risk patients can be exempted from chemotherapy, reducing treatment toxicity while lowering healthcare expenditures. Conversely, high-risk patients can initiate PD-L1 targeted therapy earlier, improving quality of life and optimizing survival benefits. At initial diagnosis, clinicians can rapidly assign risk scores using our designed scoring system to generate risk stratification reports, supporting multidisciplinary consultation decisions. Critically, our models’ advantages lie in clinical accessibility: it used routinely available clinical data, unlike costly multi-omics approaches (eg, radiomics, metagenomics, transcriptomics) that require specialized infrastructure. However, several limitations were presented in our study. First, this was a single-center design with a small sample size and potential selection bias. Second, median follow-up duration of 27 months, necessitating longer-term validation. Third, lack of dynamic perioperative biomarker monitoring. Finally, the models required further external validation in multi-center prospective cohorts to confirm clinical practicality.

Conclusion

In this study, we used nomograms to intuitively construct a prediction model of OS and PFS in patients with LARC by the inflammatory nutritional index CALLY. Higher CALLY levels were an independent protective factor for survival. Although the nomogram of OS showed strong discrimination, the PFS model not only presented a higher 3-year predictive accuracy but was more extensive in terms of clinical utility. All these results highlighted the prognostic value of CALLY in the treatment of LARC, and secondly, the nomogram of PFS could provide an individualized risk assessment before NACRT in patients and provide valuable guidance for clinical decision-making.

Data Sharing Statement

Data generated and analysed during the current study is not publicly available, due to patient confidentiality and hospital research site requirements. However, they can be obtained from the corresponding author, Chuanqing Bao, if reasonably requested.

Ethics Approval and Informed Consent

The Ethics Committee of Jiangnan University approved the study (JNU202306011RB15), and our study complied with the Declaration of Helsinki. Patients’ medical records were anonymized and de-identified before analysis. Since this study was a retrospective study using medical records from previous clinical visits and patients were recruited from across the country, the written informed consent form could not be signed in person. However, to ensure the legality of the study, we obtained consent from patients by telephone recording during telephone follow-up visits. If a patient was unable to speak or had died during the follow-up visit, consent was obtained from the family member.

Acknowledgments

We thank all the participants involved in this study.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This research was supported by Wuxi Municipal Health Commission Major Project (Grant: Z202213). Author Chuanqing Bao has received research support from the Wuxi Municipal Health Commission.

Disclosure

The authors declare no potential conflicts of interest.

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2024;74(3):229–263. doi:10.3322/caac.21834

2. Klekowski J, Chabowski M, Krzystek-Korpacka M, et al. The utility of lipidomic analysis in colorectal cancer diagnosis and prognosis—a systematic review of recent literature. Int J Mol Sci. 2024;25(14). doi:10.3390/ijms25147722

3. Shadmanov N, Aliyev V, Bakir B, et al. The shifting and evolving neoadjuvant treatments and surgical platforms on oncological outcomes and sphincter preservation in distal rectal cancer: a 23-year retrospective experience. J Gastrointest Cancer. 2025;56(1):177. doi:10.1007/s12029-025-01303-y

4. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740.

5. Serra-Aracil X, Pericay C, Badia-Closa J, et al. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab, N0, M0 rectal cancer: a multicentre randomised, controlled, Phase III trial (the TAU-TEM study). Annals Oncol. 2023;34(1):78–90. doi:10.1016/j.annonc.2022.09.160

6. Cheng Y, Luo Y, Hu Y, et al. Multiparametric MRI-based Radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer. Abdom Radiol. 2021;46(11):5072–5085. doi:10.1007/s00261-021-03219-0

7. Smith HG, Nilsson PJ, Shogan BD, et al. Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open. 2024;8(3). doi:10.1093/bjsopen/zrae038

8. Armstrong J, Balasubramanian I, Brannigan A, et al. A multicentre cohort study assessing the utility of routine blood tests as adjuncts to identify complete responders in rectal cancer following neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 2022;37(4):957–965. doi:10.1007/s00384-022-04103-z

9. Iida H, Tani M, Komeda K, et al. Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma. HPB. 2022;24(1):101–115. doi:10.1016/j.hpb.2021.06.414

10. Toda M, Musha H, Suzuki T, et al. Impact of C-reactive protein-albumin-lymphocyte index as a prognostic marker for the patients with undergoing gastric cancer surgery. Front Nutr. 2025;12. doi:10.3389/fnut.2025.1556062

11. Xi P, Huang G, Huang K, et al. The prognostic significance of the CALLY index in ampullary carcinoma: an inflammation-nutrition retrospective analysis. J Inflamm Res. 2025;18:621–635. doi:10.2147/jir.S495815

12. van Vugt JLA, Coebergh van den Braak RRJ, Lalmahomed ZS, et al. Impact of low skeletal muscle mass and density on short and long-term outcome after resection of stage I-III colorectal cancer. Eur J Surg Oncol. 2018;44(9):1354–1360. doi:10.1016/j.ejso.2018.05.029

13. Li Z, Yan G, Liu M, et al. Association of perioperative skeletal muscle index change with outcome in colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2024;15(6):2519–2535. doi:10.1002/jcsm.13594

14. Huang Z, Chen S, Yin S, et al. Development and validation of a nomogram for predicting the risk of developing gastric cancer based on a questionnaire: a cross–sectional study. Front Oncol. 2024;14. doi:10.3389/fonc.2024.1351967

15. Gou M, Qian N, Zhang Y, et al. Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.950868

16. Nagtegaal ID, Glynne-Jones R. How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement. Cancer Treatment Rev. 2020;84. doi:10.1016/j.ctrv.2020.101964.

17. Matsuda T, Sumi Y, Yamashita K, et al. Outcomes and prognostic factors of selective lateral pelvic lymph node dissection with preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis. 2018;33(4):367–374. doi:10.1007/s00384-018-2974-1

18. Horie K, Matsuda T, Yamashita K, et al. Sarcopenia assessed by skeletal muscle mass volume is a prognostic factor for oncological outcomes of rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by surgery. Eur J Surg Oncol. 2022;48(4):850–856. doi:10.1016/j.ejso.2021.10.018

19. Utsumi M, Inagaki M, Kitada K, et al. Combination of sarcopenia and systemic inflammation-based markers for predicting the prognosis of patients undergoing pancreaticoduodenectomy for pancreatic cancer. PLoS One. 2024;19(6):e0305844. doi:10.1371/journal.pone.0305844

20. Jin J, Xiong G, Peng F, et al. The ratio of skeletal muscle mass to body mass index combined with inflammatory immune markers to stratify survival of pancreatic cancer after pancreatoduodenectomy. Eur J Surg Oncol. 2024;50(7):108355. doi:10.1016/j.ejso.2024.108355

21. Yang M, Lin S-Q, Liu X-Y, et al. Association between C-reactive protein-albumin-lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: from the investigation on nutrition status and clinical outcome of common cancers study. Front Immunol. 2023;14. doi:10.3389/fimmu.2023.1131496

22. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications. Annals Surg. 2009;250(2):187–196. doi:10.1097/SLA.0b013e3181b13ca2

23. Yamashita S, Sheth RA, Niekamp AS, et al. Comprehensive complication index predicts cancer-specific survival after resection of colorectal metastases independent of RAS mutational status. Annals Surg. 2017;266(6):1045–1054. doi:10.1097/sla.0000000000002018

24. Tahiri M, Sikder T, Maimon G, et al. The impact of postoperative complications on the recovery of elderly surgical patients. Surg Endoscopy. 2015;30(5):1762–1770. doi:10.1007/s00464-015-4440-2

25. Aliyev V, Shadmanov N, Piozzi GN, et al. Comparing total mesorectal excision with partial mesorectal excision for proximal rectal cancer: evaluating postoperative and long-term oncological outcomes. Updates Surg. 2024;76(4):1279–1287. doi:10.1007/s13304-024-01926-z

26. Zhang Z-T, Xiao -W-W, Li L-R, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for initially unresectable locally advanced colon cancer: short-term outcomes of an open-label, single-centre, randomised, controlled, Phase 3 trial. eClinicalMedicine. 2024;76. doi:10.1016/j.eclinm.2024.102836

27. Okamura A, Watanabe M, Okui J, et al. Development and validation of a predictive model of therapeutic effect in patients with esophageal squamous cell carcinoma who received neoadjuvant treatment: a nationwide retrospective study in Japan. Annals Surg Oncol. 2022;30(4):2176–2185. doi:10.1245/s10434-022-12960-9

28. Kundu J, Surh Y. Inflammation: gearing the journey to cancer. Mutation Res /Rev Mutation Res. 2008;659(1–2):15–30. doi:10.1016/j.mrrev.2008.03.002

29. Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol. 2021;21(10):653–667. doi:10.1038/s41577-021-00534-x

30. Zhu M, Ma Z, Zhang X, et al. C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis. BMC Med. 2022;20(1). doi:10.1186/s12916-022-02506-x

31. Martínez-Escribano C, Arteaga Moreno F, Pérez-López M, et al. Malnutrition and increased risk of adverse outcomes in elderly patients undergoing elective colorectal cancer surgery: a case-control study nested in a cohort. Nutrients. 2022;14(1). doi:10.3390/nu14010207

32. Kim WR, Han YD, Min BS. C-reactive protein level predicts survival outcomes in rectal cancer patients undergoing total mesorectal excision after preoperative chemoradiation therapy. Annals Surg Oncol. 2018;25(13):3898–3905. doi:10.1245/s10434-018-6828-4

33. Warps AK, Tollenaar RAEM, Tanis PJ, et al. Postoperative complications after colorectal cancer surgery and the association with long-term survival. Eur J Surg Oncol. 2022;48(4):873–882. doi:10.1016/j.ejso.2021.10.035

34. Slankamenac K, Nederlof N, Pessaux P, et al. The comprehensive complication index. Annals Surg. 2014;260(5):757–763. doi:10.1097/sla.0000000000000948

35. Ortiz-López D, Marchena-Gómez J, Nogués-Ramía E, et al. Utility of a new prognostic score based on the Comprehensive Complication Index (CCI^®) in patients operated on for colorectal cancer (S-CRC-PC score). Surg Oncol. 2022;42. doi:10.1016/j.suronc.2022.101780

36. Ribeiro U. Nomogram for predicting pathologic response following neoadjuvant chemotherapy or chemoradiotherapy in patients with esophageal cancer. Annals Surg Oncol. 2023;30(4):1945–1947. doi:10.1245/s10434-023-13133-y

Introduction

Insomnia, characterized by difficulty falling or staying asleep, affects 12–20% of the global population, impairing mental and physical health and even increasing risks of hypertension, depression, and cardiovascular diseases.^1–3 Insomnia patients usually suffer heavy burdens, partly due to higher healthcare costs and cognitive dysfunction, and even increased risk of developing various serious diseases (eg, hypertension and cardiovascular disease)^1,2 (Figure 1). The main therapeutic strategies for insomnia are cognitive-behavioral therapy (CBT) and pharmacotherapy.^1–3 CBT is widely recognized as the first-line standard treatment for chronic insomnia, using various cognitive and behavioral techniques to correct dysfunctional beliefs and behavioral patterns that perpetuate insomnia.^4,5 CBT can significantly improve quality of sleep, offering long-term benefits, while medications (eg, benzodiazepines, melatonin receptor agonists, and orexin receptor antagonists) provide short-term relief but with dependency risks.⁴ However, the accessibility of CBT remains a challenge as it requires specially trained therapists.

Figure 1 The potential pathogenesis and harm of insomnia.

Alternative therapies like traditional herbal remedy (eg, Guipi capsule) have caught increasingly attentions due to their efficacy, affordable, and fewer side effects, although lack of convincingly scientific evidence.⁶ Herbal medicine for insomnia has a history of thousands of years.⁶ Guipi capsule is constituted of a traditional Chinese herbal formula. Its major components are same with the traditional herbal medicine Guipi tang (Chinese for Guipi tang or Japanese for kihi-to) that is a mixture of 12 herbs used to treat insomnia, forgetfulness, fatigue, poor memory or amnesia, anorexia, anemia, palpitations, and other neurological symptoms.⁷ This review will introduce the potential pathogenesis of insomnia, and the therapeutic efficacy and potential mechanisms of Guipi capsule for treating insomnia.

Potential Pathogenesis of Insomnia

Biofeedback Between Insomnia and Stomach Dysfunction

The classical theory of traditional Chinese medicine argues “if the stomach is not harmonized, one cannot lie peacefully.⁸ This theory indicates that dysfunction or imbalance of gastrointestinal system may cause insomnia. A survey study found that 68% of patients with functional dyspepsia, 71.2% of those with both functional dyspepsia and irritable bowel syndrome (IBS), and 50.2% of those with IBS alone self-reported sleep disturbances.⁹ Patients with functional gastrointestinal diseases often experience sleep problems, which may be attributed to the chronic pain stimuli they endure, such as persistent gastrointestinal discomfort leading to difficulty in falling asleep, disrupted sleep preventing them from falling back asleep, and overall reduced sleep duration. Individuals with digestive system disorders experience impaired sleep, while in turn, decreased sleep quality may exacerbate or trigger gastrointestinal symptoms, creating a vicious cycle of mutual influence. Therefore, improving sleep can alleviate digestive discomfort, and conversely, a better digestive state can benefit sleep quality.⁸

The current understanding of the pathophysiology of functional gastrointestinal diseases involves dysregulation of central autonomic function, visceral hypersensitivity, and neuroendocrine changes in response to stress.¹⁰ Some neurotransmitter systems involved in regulating these abnormalities, such as the ascending serotonergic system, cholinergic system, and noradrenergic arousal system, also play a vital role in sleep regulation, potentially contributing to sleep disturbances. Gastrointestinal functional disorders are often accompanied by imbalances in the intestinal microbiota and the production of inflammation in the body.^11,12 The gut houses a diverse community of microorganisms with intricate metabolic processes that significantly impact various aspects of human health, sleep regulation included.

Roles of Emotion in Insomnia

Insomnia frequently occurs in people struggling with mental issues. Chronic depression and anxiety often disrupt sleep, fueling a cycle of sleeplessness.¹³ In fact, depression is the most common mental health disorder accompanying insomnia, and the two are closely intertwined.^14–16 Research suggests that depression not only predicts insomnia but also worsens it—up to 90% of depressed patients experience poor quality of sleep, and nearly 58% of those with severe depression suffer from insomnia.¹⁷ Similarly, people prone to insomnia tend to have more severe depressive symptoms and difficulty regulating emotions, reinforcing a vicious cycle where each condition exacerbates the other.¹⁵ Anxiety-induced reductions in high-frequency heart rate variability, a marker of diminished parasympathetic nervous system activity, are associated with poorer sleep quality and increased sleep reactivity.^18,19 These findings align with existing evidence demonstrating anxiety’s role in amplifying sleep reactivity, which serves as a critical mechanism through which emotional disturbances like depression and anxiety impair sleep quality.

From a neurobiological perspective, heightened sleep reactivity appears to involve three interconnected systems: (1) dysfunctional cortical networks, (2) autonomic nervous system imbalance that characterized by sympathetic dominance and parasympathetic withdrawal, and (3) hyperactivity of the hypothalamic-pituitary-adrenal axis. Preliminary research indicates that individuals with high sleep reactivity typically exhibit this pattern of increased sympathetic activation coupled with reduced parasympathetic activity.²⁰

Emerging evidence suggests dopamine (DA) system dysfunction may play a key role in modulating sleep reactivity.²¹ As a critical monoamine neurotransmitter, DA not only regulates motivation, reward processing, and pleasure perception but also significantly influences sleep neurobiology – particularly through its action on ventral tegmental area and substantia nigra neurons.²² The connection between DA dysfunction and sleep disturbances appears bidirectional: disrupted DA signaling can contribute to anxiety and depression, which in turn exacerbate sleep reactivity and lead to insomnia.²³

Pharmacological Ingredients of Guipi Capsule and Its Potential Regulatory Mechanisms

Guipi capsule’s main bioactive ingredients amount to dozens of compounds, including sanjoinine A, jujuboside A, jujuboside B, and spinosyn (Table 1). Through the continuous collision of modern and traditional medicine, several studies have indicated mechanisms underlying the active pharmaceutical ingredients of Guipi for the treatment of insomnia (Figure 2).

Table 1 Bioactive Ingredients of the Guipi Capsule and Their Corresponding Effects

Figure 2 The mechanisms underlying the Guipi capsule for insomnia treatment. (A) The bioactive ingredients of Guipi capsule treat insomnia by dynamically regulating neurotransmitter. (B) The bioactive ingredients of Guipi capsule treat insomnia by anti-inflammation effects. (C) The bioactive ingredients of Guipi capsule treat insomnia by regulate organ functions and emotions. Upward arrows mean upregulate and downward arrows mean downregulate. Abbreviations: ASF, astragaloside isoflavan; ASI, astragaloside; APS, astragaloside polysaccharide; AGN, angelica sinensis extract; AO, atractylodes macrocephala oil.

The increased 5-hydroxytryptamine exerts anti-insominia Guipi capsule regulates HPA axis signaling and increases 5-HT levels.^7,24 Each of the individual compounds in Guipi decoction exerts anti-insomnia effects by distinct ways (Figure 2A). For example, Jujube seed contains complex bioactive ingredients for insomnia, including mountain sanjoinine A, Jujuboside A, jujuboside B, spinosin and other flavonoids. These active compounds can increase the levels of 5-HT in insomnia patients, while significantly reducing the levels of 5-HIAA. This effect of regulation can be comparable to the conventional anti-insomnia treatment with western medicines, and the anti-insomnia effect of Jujube seed is even more significant when it is combined with these western medicines.²⁵

Atractylodis macrocephalae oil (AO) was able to increase the levels of IL-10 and decrease the levels of TNF-α, IL-6, 5-HT.²⁶ Atractylodis macrocephalae polysaccharide increases tryptophan, 5-HT.²⁷ The aqueous extract of Atractylodis Macrocephalae (the main components of which are atractylenolide III and β-eudesmol exhibited inhibitory effects on DOI-induced head-twitch response (HTR).²⁸ After administration of Angelica sinensis volatiles in a mouse model of insomnia, prostaglandin E2 (PGE2), histamine (HIS), and 5-hydroxytryptamine (5-HT) levels returned to those observed in normal controls.²⁹ Poria triterpenoids may modulate 5-HT receptors expressed in cells, and inhibition of 5-HT-induced inward currents occurs in a concentration-dependent and reversible manner.³⁰ Flavonoids, liquiritigenin, glabridin, and licochalcone A are the most potent inhibitors of 5-HT-induced currents,³¹ liquiritin and isoliquiritin also significantly reduced the ratio of 5-HIAA/5-HT in the hippocampus and hypothalamus, and slowed down 5-HT metabolism.³² Astragaloside IV or astragalus saponin restores 5-HT, and monoamine oxidase deletion levels and normalizes Tph 2 mRNA expression to control values and improves memory deficits and it improves sleep disorders by this mechanism.³³

GABA Involves in Regulating the Sleep-Wake Cycle

The second mechanism by which Guipi capsule treats insomnia involves enhancing the expression of NR1 and Tau in the hippocampus, promoting GABA synthesis, and increasing serum GABA levels. Elevated GABA enhances Cl⁻influx into neurons, leading to membrane hyperpolarization, reduced neuronal excitability, and regulation of the sleep-wake cycle (Figure 1A).^34,35 GAT, including GAT-1, GAT-2, and GAT-3 isoforms, acts as the GABA transporter that maintains GABA homeostasis. GAT-1, mainly located on GABAergic neuron membranes, mediates GABA reuptake. The down-regulation of GAT-1 expression is considered to be a mechanism of self-protection after insomnia.³⁶ The up-regulation of GAT-1 caused by Guipi may be related to the release of the persistent state of excitation, and the compensatory expression of GAT-1 is gradually restored, which maintains the balance of the concentration of GABA in the neurons and synapses, and exerts its neuroinhibitory effect to improve the symptoms of insomnia.^37,38

As with the first mechanism, the various components of Guipi capsule each exert their anti-insomnia effects by directly or indirectly increasing GABA levels. Atractylenolide II/ III can maintain the activity of the recombinant GABA-A receptor.³⁹ Jujube seed contains a variety of effective chemical components against insomnia, including sanjoinine A, jujuboside A, spinosin and other flavonoids, which are able to mediate sedative and hypnotic functions through GABAergic and serotonergic systems,⁴⁰ jujuboside A and jujuboside B have significant effects on the expression and activation of GABA-A receptor,⁴¹ low-dose jujuboside A induced significant increases in the mRNA of α1, α5 and β2 subunits of GABA-A receptor in both 24-hour and 72-hour treatments, and increased the frequency of the opening of chloride channels, which had a calming and hypnotic effect.⁴² Jujuboside A not only regulates the expression of GABA receptor subunit mRNA, but also down-regulates the secretion of inflammatory cytokines related to the intestinal mucosal system, affects the cytokine network between nerve cells in the brain and exerts its specific sedative-hypnotic effect, which is a similar mechanism to that of melatonin.⁴³

Poria triterpenoids, a main component in Poria cocos, can regulate the content of GABA, menthionine and glutamate in the brain, as well as regulating the expression of GAD65 and GABA,⁴⁴ with sedative and anticonvulsant effects. There are also studies specifically targeting the signaling pathway to begin with, Poria cocos water-soluble polysaccharides (PCWP) inhibited the anxiety of rats induced by chronic sleep deprivation (CSD). PCWP intervention increased the levels of 5-HT, DA, norepinephrine, and γ-aminobutyric acid in the hypothalamus and inhibited TNF-α/nuclear factor, NF-κB signaling pathway.⁴⁵ Glabridin through GABA-A receptors to enhance GABA inhibition in neurons, thereby exerting sedative and hypnotic effects.⁴⁶ Isoliquiritin activates GABA-B receptors, thereby reducing voltage-gated Ca²⁺ channels and glutamate release in rat cortical nerve terminals. Additionally, it alleviates elevated levels of GABA and histamine.⁴⁷

The Roles of DA and NE Metabolism in Insomnia

Neural stem cells (NSC) were treated with astragaloside (ASI), astragaloside polysaccharide (APS) and astragaloside isoflavan (ASF), the main active ingredients of Astragalus. Quantitative RT-PCR results showed that ASI, APS and ASF could promote the expression of tyrosine hydroxylase and dopamine transporter protein mRNA specifically expressed in DA neurons. Meanwhile, Shh, Nurr1 and Ptx3 have been suggested to stimulate the formation of DA neurons.⁴⁸ Costunolide ameliorates have anti-apoptotic activity, which may be attributed to their regulatory effects on DA metabolism-related genes. Costunolide ameliorates are involved in the regulation of genes Nurr1, DAT and VMAT2 and are closely associated with ASYN-related DA metabolism.⁴⁹ Jujube seed extract can affect DA and NE levels in insomniac mice, exerting sedative and tranquilizing effects. This suggests that Jujube seed extract may ameliorate insomnia symptoms by modulating the levels of DA and NE.⁴² Liquiritin reduced dopamine levels to control levels;⁵⁰ Isoliquiritin antagonized the increase in striatal dopamine release.⁵¹ And licorice chalcone A (Lico. A), a flavonoid isolated from licorice, was demonstrated to attenuate the reduction of DA uptake and loss of tyrosine hydroxylase immunoreactivity in an in vitro model of PD induced by Isoliquiritin,⁵² as evidenced in experiments on cultured primary mesencephalic glia;⁵³ Lico. Isoliquiritin-induced reduction in DA uptake and loss of tyrosine hydroxylase-immunoreactive neurons in an in vitro model of PD.⁵² Dose-dependent neuroprotective effects of liquiritin during subacute NE depletion of nerve endings.⁵⁰ Atractylenolide I (AT-I) is a major constituent of Atractylodes macrocephala with a wide range of activities. AT-I was able to counteract the reduction in hippocampal 5-HT and NE concentrations induced by CUMS.⁵⁴

Anti-Inflammation Cytokines in Insomnia

As mentioned in the previous content, patients with insomnia have higher levels of inflammation, and inflammatory factors such as TNF-α and IL-1β can affect the neurotransmitter balance in the sleep center, leading to the occurrence of insomnia.⁵⁵ Therefore, reducing inflammation level is an effective method to treat insomnia (Figure 2B).

Flavonoids contained in Codonopsis, Astragalus, Atractylodes macrocephala, and Poria are natural compounds with anti-inflammatory properties.⁵⁶ Flavonoids can reduce the expression levels of inflammatory factors such as TNF-α and IL-1β as well as inhibit the NF-κB signaling pathway, suppressing the inflammatory response and thus improving the quality of sleep.⁵⁷ In addition to flavonoids, other medications have been shown to play an anti-inflammatory role in the treatment of insomnia by inhibiting the MAPK signaling pathway, including the ERK, JNK and p38 pathways. These pathways play an important role in the inflammatory response, and inhibiting their activity reduces the inflammatory response and improves sleep quality.⁵⁸ Specific drug efficacy is as follows, Astragaloside IV dose-dependently reduces serum levels of corticosterone, IL-6 and TNF-α.⁵⁹

Atractylodes macrocephala oil (AO) was able to increase the levels of IL-10 and decrease the levels of TNF-α, IL-6, and 5-HT.⁵⁹ AO can significantly inhibit systemic inflammation triggered by acute local stimuli, and exerts anti-inflammatory activity mainly by regulating the metabolic network disorders centered on glycine and arachidonic acid.⁶⁰ AO exerts anti-inflammatory effects by inhibiting pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), inflammatory mediators (HIS, 5-HT, PGE2, NO), and inflammation-related enzymes (iNOS and COX-2), as well as promoting the production of the anti-inflammatory cytokine IL-10.⁶¹ Poria cocos extract inhibited the inflammatory response induced by chronic mild stress (UCMS) and reduced the expression of p38, NF-κB, and TNF-α in the frontal cortex.⁶²

The Roles of Organ Dysfunctions and Emotions Instability in Insomnia

In addition, Guipi capsule plays an important role in regulating the spleen, stomach, liver and kidneys (Figure 1C). Guipi capsule exhibits broad therapeutic effects across multiple systems. Clinically, it demonstrates efficacy in treating non-acidic gastroesophageal reflux disease (GERD) with mood disorders when combined with omeprazole, improving gastrointestinal motility, reducing esophageal hypersensitivity, and modulating beneficial gut bacteria.^63,64 In neuropsychiatric applications, Guipi capsule shows antidepressant effects comparable to fluoxetine but with faster onset and better safety. Clinical trials reveal significant hamilton depression scale (HAMD) score improvements as early as 1 week post-treatment (P < 0.01 vs fluoxetine), with no reported adverse reactions versus fluoxetine’s 3.33% incidence (P < 0.01).⁶⁵ Mechanistically, its active components (eg, Astragalus extracts) reduce oxidative damage by suppressing ROS production and reversing 6-OHDA-induced oxidative stress.⁶⁶ Although Guipi capsule in treating insomnia show good efficacy and relatively higher safety,⁶⁵ the results are easily influenced by potential resources of bias, including publication bias and size of patients, and designs of clinical trials, the efficacy and safety of Guipi capsule need to be more strictly demonstrated based on more and better clinical trials in future. In addition, there are some other limitations: inadequate randomization and blinding for clinical trials and methodological quality of included studies.

Guipi capsule also exerts therapeutic effects through other multiple mechanisms involving both metabolic regulation and emotional modulation. The capsule influences key amino acid metabolic pathways while also regulating intestinal flora composition and promoting short-chain fatty acid production. The capsule’s emotional regulation properties are majorly mediated by its active components like astragaloside IV (ASIV) and astragalus saponins.⁶⁷ Additionally, they have been shown to mitigate anxiety responses and inflammatory reactions induced by restraint stress.⁵⁹

Furthermore, the active ingredients in Guipi capsules exert antidepressant effects by modulating the serotonin (5-HT) system, a key neurotransmitter pathway involved in mood regulation.³³ Similarly, licorice extracts appear to enhance norepinephrine (NE) and dopamine (DA) levels in the brain, contributing to their antidepressant properties.⁵⁰ Angelica sinensis extract (AGN) has been shown to mitigate stress-induced helpless behavior in rats, likely through its influence on the central noradrenergic system and upregulation of brain-derived neurotrophic factor (BDNF).⁶⁸ Meanwhile, Hairy Angelica serrulata demonstrates vasorelaxant effects in rat thoracic aorta, mediated by calcium channel blockade and increased cGMP levels in vascular smooth muscle.⁶⁹ Cycloastragenol exhibits neuroendocrine regulatory effects, reducing serum levels of stress-related factors such as NE, aldosterone, angiotensin II, and endothelin-1.⁷⁰ Additionally, pCWP has been found to counteract anxiety behaviors induced by chronic sleep deprivation in rodent models.⁴⁵

Conclusions and Discussion

Guipi capsule, a traditional Chinese herbal remedy, has been widely used in the treatment of insomnia.⁷ As mentioned above, numerous studies have shown that Guipi capsule is effective in regulating hormones and neurotransmitters, enhancing GABAergic activity,⁷¹ DA⁴⁹ and NE⁵⁰ metabolism, anti-inflammatory effects,^59–62 as well as improving gastrointestinal function and emotional health.⁶⁵ However, there are some limitations in this review: (1) The underlying mechanisms by which Guipi capsule regulates insomnia were revealed by using the single bioactive ingredient. Therefore, research should further explore the mechanism of action of Guipi capsule in depth because Guipi capsule inevitably suffers from the problem that its efficacy varies according to individual constitution and condition like most herbal medicines. (2) We could not convincingly demonstrate efficacy and safety of Guipi capsule as limited robust and well-designed clinical trials.

Overall, the application of Guipi capsule in the treatment of insomnia is potential promising, but its therapeutic efficacy and safety is expected to be further improved through in-depth research technological innovation, and well-designed clinical trials. The combination of Chinese and Western medicine in the treatment of insomnia may provide patients with more comprehensive and effective treatment options, and promote the development of the field of insomnia treatment.

Data Sharing Statement

All of data and materials can be found in references.

Acknowledgments

X. F. was supported by the 2023 Shanghai Jiao Tong University Teaching Development Fund (CTLD23J0104).

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors declare no competing interests.

References

1. Buysse DJ. Insomnia. JAMA. 2013;309(7):706–716. doi:10.1001/jama.2013.193

2. Patel D, Steinberg J, Patel P. Insomnia in the elderly: a review. J Clin Sleep Med JCSM off Publ Am Acad Sleep Med. 2018;14:1017–1024.

3. Roach M, Juday T, Tuly R, et al. Challenges and opportunities in insomnia disorder. Int J Neurosci. 2021;131(11):1058–1065. doi:10.1080/00207454.2020.1773460

4. Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med JCSM off Publ Am Acad Sleep Med. 2021;17:255–262.

5. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675–700. doi:10.1111/jsr.12594

6. Poon MM-K, Chung K-F, Yeung W-F, Yau VH-K, Zhang S-P. Classification of insomnia using the traditional Chinese medicine system: a systematic review. Evid-Based Compl Altern Med ECAM. 2012;2012:735078. doi:10.1155/2012/735078

7. Li M, Lan R, Wen Y, Shi K, Yang D. Guipi decoction for insomnia: systematic review and meta-analysis. Medicine. 2020;99(27):e21031. doi:10.1097/MD.0000000000021031

8. Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005;100(9):1914–1922. doi:10.1111/j.1572-0241.2005.00285.x

9. Fass R, Fullerton S, Tung S, Mayer EA. Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol. 2000;95(5):1195–1200. doi:10.1111/j.1572-0241.2000.02009.x

10. Schmulson MJ, Mayer EA. Evolving concepts in irritable bowel syndrome. Curr Opin Gastroenterol. 1999;15(1):16–21. doi:10.1097/00001574-199901000-00004

11. Farcas RA, Grad S, Grad C, Dumitrașcu DL. Microbiota and digestive metabolites alterations in functional dyspepsia. J Gastrointest Liver Dis JGLD. 2024;33(1):102–106. doi:10.15403/jgld-5024

12. Feng W, Yang Z, Liu Y, et al. Gut microbiota: a new target of traditional Chinese medicine for insomnia. Biomed Pharmacother Biomedecine Pharmacother. 2023;160:114344. doi:10.1016/j.biopha.2023.114344

13. Peng C, Wang K, Wang J, et al. Neural correlates of insomnia with depression and anxiety from a neuroimaging perspective: a systematic review. Sleep Med Rev. 2025;81:102093. doi:10.1016/j.smrv.2025.102093

14. Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci. 2008;10(3):329–336. doi:10.31887/DCNS.2008.10.3/dnutt

15. Predatu R, Voinescu BI, David DO. The role of emotion regulation difficulties in the relation between insomnia and depressive symptoms. Int J Behav Med. 2020;27(6):615–622. doi:10.1007/s12529-020-09903-7

16. Bjorøy I, Jørgensen VA, Pallesen S, Bjorvatn B. The prevalence of insomnia subtypes in relation to demographic characteristics, anxiety, depression, alcohol consumption and use of hypnotics. Front Psychol. 2020;11:527. doi:10.3389/fpsyg.2020.00527

17. Fang H, Tu S, Sheng J, Shao A. Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med. 2019;23(4):2324–2332. doi:10.1111/jcmm.14170

18. Chalmers JA, Quintana DS, Abbott MJ-A, Kemp AH. Anxiety disorders are associated with reduced heart rate variability: a meta-analysis. Front Psychiatry. 2014;5:80. doi:10.3389/fpsyt.2014.00080

19. Drake CL, Pillai V, Roth T. Stress and sleep reactivity: a prospective investigation of the stress-diathesis model of insomnia. Sleep. 2014;37(8):1295–1304. doi:10.5665/sleep.3916

20. Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):9–15. doi:10.1016/j.smrv.2009.05.002

21. Eban-Rothschild A, Rothschild G, Giardino WJ, Jones JR, de Lecea L. VTA dopaminergic neurons regulate ethologically relevant sleep-wake behaviors. Nat Neurosci. 2016;19(10):1356–1366. doi:10.1038/nn.4377

22. Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev. 2007;11(2):113–133. doi:10.1016/j.smrv.2006.08.003

23. Tye KM, Mirzabekov JJ, Warden MR, et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature. 2013;493(7433):537–541. doi:10.1038/nature11740

24. Chen L, Ye T, Wang X, et al. The mechanisms underlying the pharmacological effects of guipi decoction on major depressive disorder based on network pharmacology and molecular docking. Comb Chem High Throughput Screen. 2023;26(9):1701–1728. doi:10.2174/1386207325666220831152959

25. Lu Y, Bao T, Mo J, Ni J, Chen W. Research advances in bioactive components and health benefits of jujube (Ziziphus jujuba Mill.) fruit. J Zhejiang Univ Sci B. 2021;22(6):431–449. doi:10.1631/jzus.B2000594

26. Xie Y, Zhan X, Tu J, et al. Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways. J Ethnopharmacol. 2021;272:113925. doi:10.1016/j.jep.2021.113925

27. Yang H, Wu C, Chen L, et al. A. macrocephala polysaccharide induces alterations to gut microbiome and serum metabolome in constipated mice. Microb Pathog. 2023;178:106084. doi:10.1016/j.micpath.2023.106084

28. Murayama C, Wang -C-C, Michihara S, Norimoto H. Pharmacological effects of ‘jutsu’ (Atractylodis rhizome and Atractylodis lanceae rhizome) on 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head twitch response in mice (I). Mol. 2014;19:14979–14986.

29. Zhong L-J, Zhang WQ, Hua YL, et al. Metabolomic evaluation for anti-inflammatory effect of volatile oils from different preparations of Angelicae sinensis radix. Zhongguo Zhong Yao Za Zhi Zhongguo Zhongyao Zazhi China J Chin Mater Medica. 2016;41:2061–2069.

30. Lee J-H, Lee YJ, Shin J-K, et al. Effects of triterpenoids from Poria cocos wolf on the serotonin type 3a receptor-mediated ion current in xenopus oocytes. Eur J Pharmacol. 2009;615(1–3):27–32. doi:10.1016/j.ejphar.2009.04.063

31. Herbrechter R, Ziemba PM, Hoffmann KM, et al. Identification of Glycyrrhiza as the rikkunshito constituent with the highest antagonistic potential on heterologously expressed 5-HT3A receptors due to the action of flavonoids. Front Pharmacol. 2015;6:130. doi:10.3389/fphar.2015.00130

32. Wang W, Hu X, Zhao Z, et al. Antidepressant-like effects of liquiritin and isoliquiritin from Glycyrrhiza uralensis in the forced swimming test and tail suspension test in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1179–1184. doi:10.1016/j.pnpbp.2007.12.021

33. Abd Elkader H-TAE, Abdou HM, Khamiss OA, Essawy AE. Anti-anxiety and antidepressant-like effects of astragaloside IV and saponins extracted from Astragalus spinosus against the bisphenol A-induced motor and cognitive impairments in a postnatal rat model of schizophrenia. Environ Sci Pollut Res Int. 2021;28(26):35171–35187. doi:10.1007/s11356-021-12927-5

34. Oh D-R, Kim Y, Jo A, et al. Sedative and hypnotic effects of Vaccinium bracteatum Thunb. through the regulation of serotonegic and GABAA-ergic systems: involvement of 5-HT1A receptor agonistic activity. Biomed Pharmacother Biomedecine Pharmacother. 2019;109:2218–2227. doi:10.1016/j.biopha.2018.10.003

35. Jiang N, Wei S, Zhang Y, et al. Protective effects and mechanism of radix polygalae against neurological diseases as well as effective substance. Front Psychiatry. 2021;12:688703. doi:10.3389/fpsyt.2021.688703

36. Fattorini G, Melone M, Sánchez‐Gómez MV, et al. GAT-1 mediated GABA uptake in rat oligodendrocytes. Glia. 2017;65(3):514–522. doi:10.1002/glia.23108

37. Chiu C-S, Brickley S, Jensen K, et al. GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J Neurosci off J Soc Neurosci. 2005;25(12):3234–3245. doi:10.1523/JNEUROSCI.3364-04.2005

38. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2011;21(12):841–860. doi:10.1016/j.euroneuro.2011.04.002

39. Singhuber J, Baburin I, Kählig H, Urban E, Kopp B, Hering S. GABA(A) receptor modulators from Chinese herbal medicines traditionally applied against insomnia and anxiety. Phytomedicine Int J Phytother Phytopharm. 2012;19:334–340.

40. Zhou Q-H, Zhou X-L, Xu M-B, et al. Suanzaoren formulae for insomnia: updated clinical evidence and possible mechanisms. Front Pharmacol. 2018;9:76. doi:10.3389/fphar.2018.00076

41. Bian Z, Zhang W, Tang J, et al. Mechanisms underlying the action of ziziphi spinosae semen in the treatment of insomnia: a study involving network pharmacology and experimental validation. Front Pharmacol. 2021;12:752211. doi:10.3389/fphar.2021.752211

42. You Z, Xia Q, Liang F-R, et al. Effects on the expression of GABAA receptor subunits by jujuboside A treatment in rat hippocampal neurons. J Ethnopharmacol. 2010;128(2):419–423. doi:10.1016/j.jep.2010.01.034

43. Wang -X-X, Ma G-I, Xie J-B, Pang G-C. Influence of JuA in evoking communication changes between the small intestines and brain tissues of rats and the GABAA and GABAB receptor transcription levels of hippocampal neurons. J Ethnopharmacol. 2015;159:215–223. doi:10.1016/j.jep.2014.11.012

44. Shah VK, Choi JJ, Han J-Y, et al. Pachymic acid enhances pentobarbital-induced sleeping behaviors via GABAA -ergic systems in mice. Biomol Ther. 2014;22(4):314–320. doi:10.4062/biomolther.2014.045

45. Zhang -D-D, Li H-J, Zhang H-R, Ye X-C. Poria cocos water-soluble polysaccharide modulates anxiety-like behavior induced by sleep deprivation by regulating the gut dysbiosis, metabolic disorders and TNF-α/NF-κB signaling pathway. Food Funct. 2022;13(12):6648–6664. doi:10.1039/D2FO00811D

46. Jin Z, Kim S, Cho S, et al. Potentiating effect of glabridin on GABAA receptor-mediated responses in dorsal raphe neurons. Planta Med. 2013;79(15):1408–1412. doi:10.1055/s-0033-1350698

47. Lin T-Y, Lu C-W, Hsieh P-W, et al. Natural product isoliquiritigenin activates GABAB receptors to decrease voltage-gate Ca2+ channels and glutamate release in rat cerebrocortical nerve terminals. Biomolecules. 2021;11(10):1537. doi:10.3390/biom11101537

48. Gao H, Dou L, Shan L, Sun Y, Li W. Proliferation and committed differentiation into dopamine neurons of neural stem cells induced by the active ingredients of radix astragali. Neuroreport. 2018;29(7):577–582. doi:10.1097/WNR.0000000000000997

49. Ham A, Lee S-J, Shin J, Kim K-H, Mar W. Regulatory effects of costunolide on dopamine metabolism-associated genes inhibit dopamine-induced apoptosis in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2012;507(2):101–105. doi:10.1016/j.neulet.2011.10.037

50. Ahmed-Farid OA, Haredy SA, Niazy RM, Linhardt RJ, Warda M. Dose-dependent neuroprotective effect of oriental phyto-derived glycyrrhizin on experimental neuroterminal norepinephrine depletion in a rat brain model. Chem Biol Interact. 2019;308:279–287. doi:10.1016/j.cbi.2019.05.045

51. Jeon J-P, Buono RJ, Han BG, et al. Proteomic and behavioral analysis of response to isoliquiritigenin in brains of acute cocaine treated rats. J Proteome Res. 2008;7(12):5094–5102. doi:10.1021/pr800237s

52. Huang B, Liu J, Ju C, et al. Licochalcone A prevents the loss of dopaminergic neurons by inhibiting microglial activation in lipopolysaccharide (LPS)-induced parkinson’s disease models. Int J Mol Sci. 2017;18(10):2043. doi:10.3390/ijms18102043

53. Li X, Liu Q, Yu J, et al. Costunolide ameliorates intestinal dysfunction and depressive behaviour in mice with stress-induced irritable bowel syndrome via colonic mast cell activation and central 5-hydroxytryptamine metabolism. Food Funct. 2021;12(9):4142–4151. doi:10.1039/D0FO03340E

54. Gao H, Zhu X, Xi Y, et al. Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress. Exp Ther Med. 2018;15(2):1574–1579. doi:10.3892/etm.2017.5517

55. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation – PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/26140821/. Accessed November 21, 2025.

56. Al-Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, Al-Mssallem MQ. Flavonoids as potential anti-inflammatory molecules: a review. Mol. 2022;27:2901.

57. Serafini M, Peluso I, Raguzzini A. Flavonoids as anti-inflammatory agents. Proc Nutr Soc. 2010;69(3):273–278. doi:10.1017/S002966511000162X

58. Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204–7218. doi:10.18632/oncotarget.23208

59. Oh H-A, Choi HJ, Kim NJ, Kim D-H. Anti-stress effect of astragaloside IV in immobilized mice. J Ethnopharmacol. 2014;153(3):928–932. doi:10.1016/j.jep.2014.03.068

60. Zhang W-Q, Hua Y-L, Zhang M, et al. Metabonomic analysis of the anti-inflammatory effects of volatile oils of Angelica sinensis on rat model of acute inflammation. Biomed Chromatogr BMC. 2015;29(6):902–910. doi:10.1002/bmc.3372

61. Li J, Hua Y, Ji P, et al. Effects of volatile oils of Angelica sinensis on an acute inflammation rat model. Pharm Biol. 2016;54(9):1881–1890. doi:10.3109/13880209.2015.1133660

62. Huang Y-J, Hsu N-Y, Lu K-H, et al. Poria cocos water extract ameliorates the behavioral deficits induced by unpredictable chronic mild stress in rats by down-regulating inflammation. J Ethnopharmacol. 2020;258:112566. doi:10.1016/j.jep.2020.112566

63. Dai Y-K, Wu Y-B, Wen H, et al. Different traditional herbal medicines for the treatment of gastroesophageal reflux disease in adults. Front Pharmacol. 2020;11:884. doi:10.3389/fphar.2020.00884

64. Huang -T-T, Lai J-B, Du Y-L, et al. Current understanding of gut microbiota in mood disorders: an update of human studies. Front Genet. 2019;10:98. doi:10.3389/fgene.2019.00098

65. Li T, Li X, Zhang J, et al. Chemical component analysis of the traditional Chinese medicine Guipi Tang and its effects on major depressive disorder at molecular level. Heliyon. 2022;8(12):e12182. doi:10.1016/j.heliyon.2022.e12182

66. Guo L-Y, Shi F-L, Li M, et al. Astragalus protects PC12 cells from 6-hydroxydopamine-induced neuronal damage: a serum pharmacological study. Chin J Physiol. 2021;64(1):24–31. doi:10.4103/CJP.CJP_50_20

67. He Q, Han C, Huang L, et al. Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation. J Cell Mol Med. 2020;24(16):9349–9361. doi:10.1111/jcmm.15586

68. Lee B, Sur B, Shim I, Lee H, Hahm D-H. Angelica gigas ameliorate depression-like symptoms in rats following chronic corticosterone injection. BMC Complement Altern Med. 2015;15(1):210. doi:10.1186/s12906-015-0746-9

69. Ko FN, Wu TS, Liou MJ, Huang TF, Teng CM. Vasorelaxation of rat thoracic aorta caused by osthole isolated from Angelica pubescens. Eur J Pharmacol. 1992;219(1):29–34. doi:10.1016/0014-2999(92)90576-P

70. Wang J, Wu M-L, Cao S-P, et al. Cycloastragenol ameliorates experimental heart damage in rats by promoting myocardial autophagy via inhibition of AKT1-RPS6KB1 signaling. Biomed Pharmacother Biomedecine Pharmacother. 2018;107:1074–1081. doi:10.1016/j.biopha.2018.08.016

71. Liu L, Zou Z, Yang J, et al. Jianpi jieyu decoction, an empirical herbal formula, exerts psychotropic effects in association with modulation of gut microbial diversity and GABA activity. Front Pharmacol. 2021;12:645638. doi:10.3389/fphar.2021.645638

Drawing on insight from the firm’s global network of partners, the analysis provides a forward look at the issues likely to demand insurers’ attention as the global risk landscape continues to shift over the next 12 months. 

Clyde & Co’s emerging risk predictions for insurers in 2026: 

• Social media addiction
• Space
• Next generation nuclear
• Sanctions
• Head office liability 
• Litigation funding

Since September 2022, the Europeana Research Community and the EuropeanaTech Community have supported a Working Group on Datasheets for Digital Cultural Heritage Datasets. The Working Group addresses a critical matter for cultural heritage institutions managing digital collections, that is, providing data reusers with the context needed for reusing data.

Specifically, the working group has focused on datasheets as a standardised publication format for documenting datasets (for example, corpora of digitised books and newspapers, bibliographic datasets, digitised artworks), with the goal to support cultural heritage institutions and other data providers to describe their data assets in a way compliant with the FAIR principles, enabling an efficient inclusion into reuse workflows. This focus has also brought forward the efforts to affirm a ‘Collection as Data’ approach in the common European data space for cultural heritage, concretely expressed by the development of the ‘Collections as Data’ workflow, in which documentation is addressed as one of the ten steps suggested for curating datasets.

After realising their datasheet template – Version 1 in September 2023, and presenting it at events across Europe, this year the Working Group members have organised a series of workshops to test and refine the template with professionals and researchers interested in digital curation across and beyond the Europeana Initiative. This series included a workshop with those working on similar initiatives in Europe (such as data envelopes at the KNAW | The Royal Netherlands Academy of Arts and Sciences) and a highly attended workshop open to the public embedded into the programme of the Europeana Aggregators’ Forum meeting in Spring.

This approach – nurtured by the spirit of the Europeana communities that are based on knowledge-sharing and bottom-up development of the cultural heritage sector – led to the release of the datasheet template – Version 2 in July 2025.

What’s new in Version 2

The new datasheet template is structured in six sections, which combine technical and ethical aspects that documentation should take into account: title, description, distribution, composition, data collection process, examples and considerations for using the data. While the core aims of the template remain the same, Version 2 brings several structural improvements. The updated version features a modular information architecture organised into three levels of depth, with a minimal set of mandatory fields. This design allows the template to better accommodate the diversity and complexity of digital heritage collections and to be used meaningfully across very different types of datasets, while clearly indicating what is known, unknown and not applicable.

In addition to these structural updates, Version 2 takes the first steps toward machine-readability, in line with the current developments around the common European data space for cultural heritage. Fields identified as mandatory within the template have been mapped to the Data Catalogue Vocabulary Application Profile for data portals in Europe (DCAT-AP), a specification for describing public sector datasets in Europe. Aligning with this standard enables discoverability in data portals and compatibility with automated workflows, while keeping the primary focus of the template on human readability and usability.

What’s next and how to get involved

The Working Group continues to refine the template, focusing on interoperability and facilitating its adoption. Current priorities include an overall alignment with DCAT-AP, and gathering new use cases, whilst developing an open-source tool to support the creation of documentation for datasets, which will be finalised and made available in open source by next year. The datasheet template – Version 2 will serve as a basis to define minimum requirements for sharing datasets through the upcoming data catalogue of the common European data space for cultural heritage.

Explore the datasheet template – Version 2, try it out in your own context, and share your feedback by writing an email to [email protected]! Your contributions will help shape the next steps in this community-driven project.

Meet the Working Group on site or online at Fantastic Futures 2025

Working Group representatives will present these updates at the Fantastic Futures 2025 conference organised by AI4LAM and hosted at the British Library on 3–5 December 2025, in a lightning talk highlighting Version 2 within a group of initiatives focusing on documenting datasets: Write it down! Fostering Responsible Reuse of Cultural Heritage Data with Interoperable Dataset Descriptions. Tickets for online attendance are now available for free – register now.